Nikola's stock crashes after announcing cancelation of contract with Republic Services for 2,500 garbage trucks

The undoing of Nikola continues. Today, the company announced the termination of its contract with Republic Services for 2,500 garbage trucks. Announced back in August, the deal had Nikola building garbage trucks in 2023 with on-road testing scheduled for 2024.

• 
  Nikola Tumbles After Losing Electric Garbage Truck Order

  Bloomberg
• 
  Nikola Stock Investors Suffer Another 'Gut Punch' As One More Deal Unravels

  Investor's Business Daily

The new stimulus deal includes 6 tax breaks that could help Americans

The $900 billion coronavirus relief deal includes six tax breaks for Americans. Another three tax benefits show up in the government spending bill attached to the package.

• 
  House and Senate pass $900 billion stimulus deal

  Yahoo Money
• 
  Congress passes massive COVID relief and government funding bill

  CBS MoneyWatch

Trump wants you to get a bigger stimulus check — so what now?

The president is demanding $2,000 payments, not $600. What can he do?

• 
  Stimulus check update: When will you get your second payment?

  Yahoo Money
• 
  House and Senate pass $900 billion stimulus deal

  Yahoo Money

Is Ocugen Stock Still Worth Buying After Its 800%-Plus Rally? Analyst Weighs In

Can you feel the ground moving beneath your feet? Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market.Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway.The agreement stipulates Ocugen will hold the vaccine’s U.S. rights, and the remaining details are expected to be finalized over the coming weeks.Considering Bharat’s reputation for world-class R&D and manufacturing capabilities in vaccines and bio-therapeutics, H.C. Wainwright analyst Swayampakula Ramakanth thinks the company is a “suitable partner.”Ramakanth believes the “broad immunity targeting different components of the virus could potentially provide better protection against emerging mutant viruses, such as the one currently circulating in the UK.” With this in mind, in the Phase 1 study, COVAXIN has shown robust antibody responses against spike (S1) protein, receptor-binding domain (RBD) and the nucleocapsid (N) protein of SARS-CoV-2. “More importantly,” the 5-star analyst added, “COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum," which, the analyst believes," bodes well for the success of the ongoing Phase 3 trial in India.”Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXIN’s development.However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of “insight into the U.S. regulatory pathway or commercial strategy,” Ramakanth stays on the sidelines for now.Accordingly, the analyst rates OCGN a Neutral (i.e. Hold) without suggesting a price target. (To watch Ramakanth’s track record, click here)In contrast, all 3 other analysts who have recently posted an Ocugen review rate the stock a Buy. However, the Strong Buy consensus rating is backed with a $0.9 price target, which implies downside of 68% from current levels. This is most likely a result of the stock’s meteoric rise and analysts’ inability to turnaround new price targets so quickly. (See OCGN stock analysis on TipRanks)To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.